facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2022
vol. 109
 
Share:
Share:
abstract:
Case report

Position of omalizumab therapy in the treatment of spontaneous chronic urticaria. A case series and literature review

Aleksander Obtułowicz
1
,
Magdalena Pirowska
1
,
Judyta Maciejowska
1
,
Anna Wojas-Pelc
1

  1. Department of Dermatology, Jagiellonian University Medical College, Krakow, Poland
    Katedra i Klinika Dermatologii, Uniwersytet Jagielloñski Collegium Medicum, Kraków, Polska
Dermatol Rev/Przegl Dermatol 2022, 109, 74-82
Online publish date: 2022/05/31
View full text Get citation
 
PlumX metrics:
Introduction
Urticaria is an etiopathologically complex disease. Current guidelines recommend an algorithm for urticaria treatment, which includes omalizumab as third line treatment.

Objective
To evaluate clinical efficacy of omalizumab in patients with urticaria.

Case report
Three women were treated with omalizumab for spontaneous chronic urticaria, resistant to standard therapy patterns. The concentration of total IgE determined in patients during omalizumab therapy in the first case was originally maintained at a low level, while during the continuation of the treatment it increased four times. In the second case, originally a near 2-fold decrease of total IgE concentration was observed, then it increased 1.5 times.

Conclusions
The obtained data confirm a high efficacy of omalizumab therapy in patients with spontaneous chronic urticaria. Fast and complete or nearly complete resolution of urticaria symptoms was observed during the treatment.

keywords:

treatment, urticaria, omalizumab



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.